drugset / Trial / NCT00652574
Dasatinib in Resectable Malignant Pleural Mesothelioma
Phase 1
Completed
56 enrolled
M.D. Anderson Cancer Center
Bristol-Myers Squibb · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn how dasatinib affects biomarker levels in patients with malignant pleural mesothelioma that may be able to be removed by surgery. The safety and effectiveness of this drug will also be studied. This research study is financially supported by the United States Department of Defense.
Timeline
- Start
- 2008-03-12
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 70 mg | Oral |